Quick Dispatch:
Your retatrutide trial VisualAbstract: Retatrutide reduces body weight by 17.5% in patients with obesity orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your retatrutide trial VisualAbstract: Retatrutide reduces body weight by 17.5% in patients with obesity ships.
Need Help?
Questions about retatrutide trial VisualAbstract: Retatrutide reduces body weight by 17.5% in patients with obesity, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for retatrutide trial VisualAbstract: Retatrutide reduces body weight by 17.5% in patients with obesity in your area.
Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:
26.45
01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
25.98
Retatrutide Shows 28% Weight Loss in 80 Weeks
29.04
New Weight Loss Drug Retatrutide: My Patient's 85-Pound Journey (And What the Trials Don't Tell You)
22.76
Lilly's triple agonist delivers up to 71.2 lbs of weight loss
24.24
The numbers from Lilly's Phase 3 retatrutide trial dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user
27.03
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
27.93
